In this article, we will discuss Aldesleukin (Indications). So, let’s get started.
Aldesleukin is indicated for the treatment of adults with metastatic renal cell
carcinoma (metastatic RCC).
Aldesleukin is indicated for the treatment of adults with metastatic melanoma.
Careful patient selection is mandatory prior to the administration of Proleukin.
Evaluation of clinical studies to date reveals that patients with more favorable ECOG
performance status (ECOG PS 0) at treatment initiation respond better to Aldesleukin, with a
higher response rate and lower toxicity. Therefore, selection of patients for treatment should include assessment of performance status.
Experience in patients with ECOG PS >1 is extremely limited.
Aldesleukin is contraindicated in patients with a known history of hypersensitivity
to interleukin-2 or any component of the Aldesleukin formulation.
Aldesleukin is contraindicated in patients with an abnormal thallium stress test or abnormal pulmonary function tests and those with organ allografts. Retreatment with Aldesleukin is contraindicated in patients who have experienced the following drug-related toxicities while receiving an earlier course of therapy:
• Sustained ventricular tachycardia (≥5 beats)
• Cardiac arrhythmias not controlled or unresponsive to management
• Chest pain with ECG changes, consistent with angina or myocardial infarction
• Cardiac tamponade
• Intubation for >72 hours
• Renal failure requiring dialysis >72 hours
• Coma or toxic psychosis lasting >48 hours
• Repetitive or difficult to control seizures
• Bowel ischemia/perforation
• GI bleeding requiring surgery.